Clinical Trials Logo

COVID-19 clinical trials

View clinical trials related to COVID-19.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT04848584 Not yet recruiting - COVID-19 Clinical Trials

Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California

Start date: April 19, 2021
Phase:
Study type: Observational

The primary objective of this study is to determine the vaccine effectiveness of 2 doses of Pfizer-BioNTech BNT162b2 vaccine against COVID-19-associated hospitalization. There will be a large retrospective database study using two parallel study designs: a test-negative case-control design and a retrospective cohort design. Exploratory analyses of VE estimates by strain type will be conducted.

NCT ID: NCT04848493 Not yet recruiting - COVID-19 Clinical Trials

National Project on Vaccines, COVID-19 and Frail Patients

VAX4FRAIL
Start date: April 20, 2021
Phase:
Study type: Observational

This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence, due to their underlying diseases or ongoing therapies.

NCT ID: NCT04847375 Not yet recruiting - COVID-19 Clinical Trials

Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients

CovidSurf
Start date: April 20, 2021
Phase: N/A
Study type: Interventional

Covid-19 disease is one of the most important health system challenges which is the result of the recent SARS CoV-2 virus outbreak. So far, despite the use of different types of pharmaceuticals, none has been served as a curative treatment and research is continued to find one or more effective drugs; either palliative or curative ones. One of the most important clinical problems in Covid-19 patients is lung involvement, which may causes significant sequels; leading to a main part of morbidity and/or mortality. Surfactant is one of the drugs that can have valuable effects on the lungs, both by reducing the alveolar surface tension and by exerting immunomodulatory effects. In a previous study by the same team, favorable effects were seen in intubated patients; however, the aim of this study was to evaluate the effect of exogenous nebulized surfactant in the pre-intubation stages of the disease.

NCT ID: NCT04847141 Not yet recruiting - COVID-19 Clinical Trials

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients

Start date: April 19, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human) 20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic participants who remain asymptomatic, i.e., who do not develop symptomatic coronavirus disease 2019 (COVID-19) through Day 14 as per the protocol defined criteria.

NCT ID: NCT04847102 Not yet recruiting - COVID-19 Clinical Trials

A Phase III Clinical Study to Evaluate the Protective Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate in Population Aged 18 Years and Above

Start date: May 28, 2021
Phase: Phase 3
Study type: Interventional

Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly assigned into the study group and the control group at a ratio of 1:1 (14,000 in each group) to be intramuscularly administered with the investigational vaccine or placebo in a 2-dose regimen at an interval of 28 days. The experimental vaccines will be cross-vaccinated after available data of the investigational vaccine show that expected efficacy and good safety have been achieved (i.e., subjects in the study group will be vaccinated with placebo and those in the control group will be vaccinated with the investigational vaccine in the same schedule as stated above ). After the completion of the second dose for crossover vaccination, subjects will be followed up for 12 months for safety observation. An immunogenicity subgroup (n≥3000) and a reactogenicity subgroup (n≥6000) will also be included in this trial to evaluate the humoral immunity induced by the investigational vaccine and the solicited adverse events observed within 7 days post immunization. All enrolled subjects will be followed up for the evaluation of protective efficacy as well, which will be primarily characterized by the incidence rate (person-year) of COVID-19 cases collected from 14 days after complete series. Adverse events will be collected over 0-28 days after each vaccination and serious adverse events will be collected from Dose 1 through 12 months post complete series.

NCT ID: NCT04844541 Not yet recruiting - COVID-19 Clinical Trials

Prophylaxis and Treatment of COVID-19

PROTECT-APT
Start date: April 2021
Phase:
Study type: Observational

Adaptive platform trial to enable the evaluation of investigational products for early treatment and post-exposure prophylaxis of COVID-19.

NCT ID: NCT04844515 Not yet recruiting - COVID-19 Clinical Trials

The ESPERES Prospective Cohort of Healthcare Workers in France: Study on COVID-19 Vaccine and the COVID-19 Pandemic (ESPERES_COVID19)

Start date: April 9, 2021
Phase:
Study type: Observational [Patient Registry]

This is the first study performed within the ESPERES cohort, related to prevention against COVID-19, in particular vaccination against COVID-19 and more broadly on the COVID-19 pandemic. ESPERES is a national prospective e-cohort study providing a resource for collecting information on healthcare workers (HCWs) currently working in France. The overall goal of ESPERES is to develop the infrastructure necessary to create and engage a community of HCWs who may be eligible for participation in future research studies. ESPERES is set up to answer research questions, in the field of prevention for HCWs, prevention for their own health, that of their relatives, their colleagues, and users of the hospital. These research questions will be carried out in the context of specific subsequent studies.

NCT ID: NCT04844307 Not yet recruiting - COVID-19 Clinical Trials

Comparing Inpatient COVID-19 Outcomes in 2 Different PT Dosing Groups

CCPT
Start date: May 2021
Phase: N/A
Study type: Interventional

The objective of this study is to compare the effects of twice-a-day 15-minute sessions of inpatient physical therapy (PT) to the standard daily 30 minute sessions. The patient outcomes that will be evaluated will be length of stay, change in functional status, and disposition (home/acute rehab vs. subacute/LTAC/death) in patients admitted with COVID-19.

NCT ID: NCT04842448 Not yet recruiting - COVID-19 Clinical Trials

Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome

HOT-LoCO
Start date: June 2021
Phase: Phase 2
Study type: Interventional

Long COVID Syndrome (LCOV) or (Long COVID) is defined as 'signs and symptoms that develop during or following an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis'. 1 in 10 infected individuals may suffer persistent symptoms, and we are facing an emerging problem that will severely affect individuals, health care systems and society for years to come. We explore hyperbaric oxygen administered in a randomized placebo-controlled clinical trial as a potential treatment for patients suffering from Long COVID. The overall hypothesis to be evaluated is that hyperbaric oxygen (HBO2) alleviates symptoms associated with Long COVID.

NCT ID: NCT04842435 Not yet recruiting - COVID-19 Clinical Trials

Clinical Study in the Treatment of Patients With Moderate Course of COVID-19

Start date: April 9, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Study of safety, efficacy and pharmacokinetics, dose selection